Selected research
Industry Research
Betahistine Industry Research Report 2026
Market perspective
The global Betahistine market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Betahistine is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Betahistine is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Betahistine is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Betahistine include TOWA PHARMACEUTICAL CO., LTD, Takeda Pharmaceutical Company Limited, Mylan, Orion Corporation, Nichi-Iko Pharmaceutical, HENNIG ARZNEIMITTEL GmbH & Co. KG, EA Pharma Co., Ltd., DOC Generici and Disphar International B.V., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Betahistine market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Betahistine Market by Company
TOWA PHARMACEUTICAL CO., LTD
Takeda Pharmaceutical Company Limited
Mylan
Orion Corporation
Nichi-Iko Pharmaceutical
HENNIG ARZNEIMITTEL GmbH & Co. KG
EA Pharma Co., Ltd.
DOC Generici
Disphar International B.V.
Ciclum Farma Unipessoal
Betahistine Segment by Type
8mg
25mg
Others
Betahistine Segment by Application
Cerebral Thrombosis
Cerebral Embolism
Others
Betahistine Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Betahistine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Betahistine and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Betahistine.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Betahistine manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Betahistine by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Betahistine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- 8mg
- 25mg
- Others
Applications
- Cerebral Thrombosis
- Cerebral Embolism
- Others
Companies covered
- TOWA PHARMACEUTICAL CO., LTD
- Takeda Pharmaceutical Company Limited
- Mylan
- Orion Corporation
- Nichi-Iko Pharmaceutical
- HENNIG ARZNEIMITTEL GmbH & Co. KG
- EA Pharma Co., Ltd.
- DOC Generici
- Disphar International B.V.
- Ciclum Farma Unipessoal
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Betahistine Market Size (2021-2032)
- 2.2.2 Global Betahistine Sales (2021-2032)
- 2.2.3 Global Betahistine Market Average Price (2021-2032)
- 2.3 Betahistine by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 8mg
- 2.3.3 25mg
- 2.3.4 Others
- 2.4 Betahistine by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Cerebral Thrombosis
- 2.4.3 Cerebral Embolism
- 2.4.4 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Betahistine Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Betahistine Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Betahistine Revenue of Manufacturers (2021-2026)
- 3.4 Global Betahistine Average Price by Manufacturers (2021-2026)
- 3.5 Global Betahistine Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Betahistine, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Betahistine, Product Type & Application
- 3.8 Global Manufacturers of Betahistine, Established Date
- 3.9 Global Betahistine Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 TOWA PHARMACEUTICAL CO., LTD
- 4.1.1 TOWA PHARMACEUTICAL CO., LTD Company Information
- 4.1.2 TOWA PHARMACEUTICAL CO., LTD Business Overview
- 4.1.3 TOWA PHARMACEUTICAL CO., LTD Betahistine Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 TOWA PHARMACEUTICAL CO., LTD Betahistine Product Portfolio
- 4.1.5 TOWA PHARMACEUTICAL CO., LTD Recent Developments
- 4.2 Takeda Pharmaceutical Company Limited
- 4.2.1 Takeda Pharmaceutical Company Limited Company Information
- 4.2.2 Takeda Pharmaceutical Company Limited Business Overview
- 4.2.3 Takeda Pharmaceutical Company Limited Betahistine Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Takeda Pharmaceutical Company Limited Betahistine Product Portfolio
- 4.2.5 Takeda Pharmaceutical Company Limited Recent Developments
- 4.3 Mylan
- 4.3.1 Mylan Company Information
- 4.3.2 Mylan Business Overview
- 4.3.3 Mylan Betahistine Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Mylan Betahistine Product Portfolio
- 4.3.5 Mylan Recent Developments
- 4.4 Orion Corporation
- 4.4.1 Orion Corporation Company Information
- 4.4.2 Orion Corporation Business Overview
- 4.4.3 Orion Corporation Betahistine Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Orion Corporation Betahistine Product Portfolio
- 4.4.5 Orion Corporation Recent Developments
- 4.5 Nichi-Iko Pharmaceutical
- 4.5.1 Nichi-Iko Pharmaceutical Company Information
- 4.5.2 Nichi-Iko Pharmaceutical Business Overview
- 4.5.3 Nichi-Iko Pharmaceutical Betahistine Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Nichi-Iko Pharmaceutical Betahistine Product Portfolio
- 4.5.5 Nichi-Iko Pharmaceutical Recent Developments
- 4.6 HENNIG ARZNEIMITTEL GmbH & Co. KG
- 4.6.1 HENNIG ARZNEIMITTEL GmbH & Co. KG Company Information
- 4.6.2 HENNIG ARZNEIMITTEL GmbH & Co. KG Business Overview
- 4.6.3 HENNIG ARZNEIMITTEL GmbH & Co. KG Betahistine Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 HENNIG ARZNEIMITTEL GmbH & Co. KG Betahistine Product Portfolio
- 4.6.5 HENNIG ARZNEIMITTEL GmbH & Co. KG Recent Developments
- 4.7 EA Pharma Co., Ltd.
- 4.7.1 EA Pharma Co., Ltd. Company Information
- 4.7.2 EA Pharma Co., Ltd. Business Overview
- 4.7.3 EA Pharma Co., Ltd. Betahistine Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 EA Pharma Co., Ltd. Betahistine Product Portfolio
- 4.7.5 EA Pharma Co., Ltd. Recent Developments
- 4.8 DOC Generici
- 4.8.1 DOC Generici Company Information
- 4.8.2 DOC Generici Business Overview
- 4.8.3 DOC Generici Betahistine Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 DOC Generici Betahistine Product Portfolio
- 4.8.5 DOC Generici Recent Developments
- 4.9 Disphar International B.V.
- 4.9.1 Disphar International B.V. Company Information
- 4.9.2 Disphar International B.V. Business Overview
- 4.9.3 Disphar International B.V. Betahistine Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Disphar International B.V. Betahistine Product Portfolio
- 4.9.5 Disphar International B.V. Recent Developments
- 4.10 Ciclum Farma Unipessoal
- 4.10.1 Ciclum Farma Unipessoal Company Information
- 4.10.2 Ciclum Farma Unipessoal Business Overview
- 4.10.3 Ciclum Farma Unipessoal Betahistine Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Ciclum Farma Unipessoal Betahistine Product Portfolio
- 4.10.5 Ciclum Farma Unipessoal Recent Developments
5 Global Betahistine Market Scenario by Region
- 5.1 Global Betahistine Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Betahistine Sales by Region: 2021-2032
- 5.2.1 Global Betahistine Sales by Region: 2021-2026
- 5.2.2 Global Betahistine Sales by Region: 2027-2032
- 5.3 Global Betahistine Revenue by Region: 2021-2032
- 5.3.1 Global Betahistine Revenue by Region: 2021-2026
- 5.3.2 Global Betahistine Revenue by Region: 2027-2032
- 5.4 North America Betahistine Market Facts & Figures by Country
- 5.4.1 North America Betahistine Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Betahistine Sales by Country (2021-2032)
- 5.4.3 North America Betahistine Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Betahistine Market Facts & Figures by Country
- 5.5.1 Europe Betahistine Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Betahistine Sales by Country (2021-2032)
- 5.5.3 Europe Betahistine Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.6 Asia Pacific Betahistine Market Facts & Figures by Country
- 5.6.1 Asia Pacific Betahistine Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Betahistine Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Betahistine Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Betahistine Market Facts & Figures by Country
- 5.7.1 South America Betahistine Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Betahistine Sales by Country (2021-2032)
- 5.7.3 South America Betahistine Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.8 Middle East and Africa Betahistine Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Betahistine Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Betahistine Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Betahistine Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Betahistine Sales by Type (2021-2032)
- 6.1.1 Global Betahistine Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Betahistine Sales Market Share by Type (2021-2032)
- 6.2 Global Betahistine Revenue by Type (2021-2032)
- 6.2.1 Global Betahistine Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Betahistine Revenue Market Share by Type (2021-2032)
- 6.3 Global Betahistine Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Betahistine Sales by Application (2021-2032)
- 7.1.1 Global Betahistine Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Betahistine Sales Market Share by Application (2021-2032)
- 7.2 Global Betahistine Revenue by Application (2021-2032)
- 7.2.1 Global Betahistine Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Betahistine Revenue Market Share by Application (2021-2032)
- 7.3 Global Betahistine Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Betahistine Value Chain Analysis
- 8.1.1 Betahistine Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Betahistine Production Mode & Process
- 8.2 Betahistine Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Betahistine Distributors
- 8.2.3 Betahistine Customers
9 Global Betahistine Analyzing Market Dynamics
- 9.1 Betahistine Industry Trends
- 9.2 Betahistine Industry Drivers
- 9.3 Betahistine Industry Opportunities and Challenges
- 9.4 Betahistine Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst